 PITTSBURGH, Oct. 19, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc., Krystal NASDAQ: KRYS, the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy candidate for the treatment of cystic fibrosis, in a poster at the North American Cystic Fibrosis Conference NACFC taking place virtually November 2 5, 2021. The data include more detailed results from the IND-enabling good laboratory practice GLP toxicology study of KB407 from which top line results were previously announced. The company was recently granted approval to conduct a Phase 1 clinical study of inhaled KB407 in patients with cystic fibrosis CF in Australia by the Bellberry Human Research Ethics Committee HREC and plans to initiate a clinical trial in the United States in 2022. 